Latest news

Today, 8:50 PM

SVB Leerink analyst Andrew Berens maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and raises the price target from $21 to $25.

1 minute read

Analyst Ratings

4 Analysts Have This to Say About Deciphera Pharmaceuticals

Today, 8:50 PM

Within the last quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings:

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 29, 2022

Today, 8:50 PM

Upgrades

AERI

1 minute read

Cowen & Co. Initiates Coverage On Deciphera Pharmaceuticals with Outperform Rating, Announces Price Target of $25

Today, 8:50 PM

Cowen & Co. analyst Tyler Van Buren initiates coverage on Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform rating and announces Price Target of $25.

1 minute read

Deciphera’s Cancer Drug Tops Pfizer’s Sutent On Safety Front In Gastrointestinal Cancer

By Vandana Singh

Today, 8:50 PM

The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced…

1 minute read

HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $20

Today, 8:50 PM

HC Wainwright & Co. analyst Andrew Fein maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the price target from $15 to $20.

1 minute read

JMP Securities Upgrades Deciphera Pharmaceuticals to Market Outperform, Announces $23 Price Target

Today, 8:50 PM

JMP Securities analyst Reni Benjamin upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Market Perform to Market Outperform and announces $23 price target.

34 minute read

Earnings

Earnings Scheduled For August 4, 2022

Today, 8:50 PM

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

AAOI

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session